The survival of patients enrolled in a global direct-to-patient cancer medicine donation program: The Glivec International Patient Assistance Program (GIPAP)

The Glivec International Patient Assistance Program (GIPAP) is a unique direct-to-patient program that provides imatinib (Glivec) at no cost to eligible patients in low- and middle-income countries (LMICs) with chronic myelogenous leukemia (CML) or gastrointestinal stromal tumor (GIST). This paper analyses the output, outcome and impact of the program between 2001 and 2014 using the data collected by the Max Foundation. Method: We extracted data on GIPAP patients’ country of residence, sex, diagnosis, date of enrollment in GIPAP, age at enrollment, case closure date, and reason for closure from The Max Foundation database covering the period 2001 to 2014. We used Kaplan-Meier method to assess the survival rate of patients in GIPAP and used the proportional hazard regression model to estimate the effect of different variables on patients’ survival. Findings: About 63,000 GIPAP patients in 93 countries received over 71 million defined daily doses (DDD) of imatinib between 2001 and 2014. Our analysis showed that GIPAP patients had a 5-year survival rate of 89% which compares favorably to survival in high income countries despite the challenges of delivering cancer care in LMICs. Age at enrollment into the program, sex, duration between diagnosis and enrollment into program, year of enrollment, and patients’ diagnosis (CML vs non-CML) were factors that influenced survival

The levels of T cells (T-helper/T-suppressor and natural killer cells) in patients with sickle cell anemia who undergo erythrocytapheresis.

TEZ7475Tez (Yüksek Lisans) -- Çukurova Üniversitesi, Adana, 2009.Kaynakça (s.92-103) var.xii, 107 s. : rnk.res. ; 29 cm.Sickle cell anemia (SCA) is an autosomal recessive hemoglobinopathy characterized by hemolytic anemia, intermittent occlusion of small vessels leading to acute and chronic tissue ischemia, and organ dysfunction. Patients with SCA, particularly children, have an increased susceptibility to infections due to immune function impairment and functional asplenia, and severe infections can trigger vasoocclusive crises in these patients. Despite the fact that erythrocytapheresis has been shown to be beneficial in the treatment and prevention of complications related to sickling processes, neither the effect of erythrocytapheresis on the level of T cell subsets nor the role of lymphocytes in the immunocompromised state in SCA has been fully defined. In this study, flow cytometric analyses were performed in SCA patients before and after erythrocytapheresis to assess the influence of apheresis procedure on the levels of T cell subsets...Orak hücre anemisi (OHA); kronik hemolitik anemi ve küçük damarlarda tıkanmalar sonucunda gelişen akut/kronik doku nekrozu ve organ disfonksiyonu ile karakterize, otozomal resesif geçişli bir hemoglobinopatidir. Orak hücre anemili hastalarda, özellikle çocuklarda, immün fonksiyon bozukluğu ve fonsiyonel aspleni nedeniyle enfeksiyonlara eğilim artmıştır ve ağır enfeksiyonlar vazooklüzif krizler için uygun bir ortam oluşturmaktadır. Eritrosit aferezi, oraklaşmaya bağlı komplikasyonların tedavisinde ve önlenmesinde yararlı bulunmuştur. Bununla birlikte, immün bozukluğu olan orak hücre anemili olgularda T lenfositlerin rolü ve eritrosit aferezinin T hücre alt grupları üzerine etkisi henüz tam olarak tanımlanmamıştır. Çalışmamızda, eritrosit aferezi uygulamasının T hücre düzeyleri üzerine etkisini belirlemek amacıyla, 39 OHA'lı hastada aferez öncesinde ve sonrasında T lenfosit işaretleyicileri ile akım sitometrik analiz yapıldı

A case report of the cascade filtration system: A safe and effective method for low-density lipoprotein apheresis during pregnancy

PubMedID: 18937724Women with familial hypercholesterolemia (FH) should be treated effectively during pregnancy, as elevated low-density lipoprotein cholesterol (LDL-C) levels may result in life-threatening consequences. Hydroxymethylglutaryl- coenzyme A reductase inhibitors are contraindicated during pregnancy, therefore LDL apheresis should be considered in the management of such pregnant cases. There are five different methods of selective LDL apheresis: heparin-induced extracorporeal LDL precipitation, double filtration plasmapheresis, direct adsorption of lipoproteins, dextran sulfate adsorption, and LDL immunoadsorption. The cascade filtration system is another modern and effective method for the extracorporeal elimination of LDL-C, although it is not as selective as the methods mentioned above. Herein, we present the case of a pregnant woman with heterozygous FH and extremely elevated LDL-C levels who has been successfully treated with the cascade filtration system until delivery. As far as we can ascertain, LDL apheresis with the cascade filtration system during pregnancy has not yet been reported in the literature. © 2008 The Authors

Donor granulocyte transfusion [Donör granülosi·t transfüzyonu]

The risk of developing life threatening bacterial and fungal infections is significantly high in neutropenic patients. In such cases, it is essential to regulate neutropenia, to apply proper and efficient antimicrobial agent and to continue with the other supporting treatments. Donor Granulocyte Transfusion (DGT) aims to provide polymorphonuclear leukocytes in sufficient amount, quality and functionality. Recent advances in early infection detection, development of more efficient antimicrobial agents, and use of recombinant hematopoietic growth factors and infection risks associated with transfusion and HLA alloimmunization as well as life-threatening acute toxicities has limited the DGT utilization. In recent years, DGT has become topic of interest again as a result of increased presence; thus harvesting of granulocytes in circulation, which can be attributed to development of hematopoiteic growth factors. In this paper, we have a look at, indications, clinical usage and technology of granulocyte collection and transfusion

Intra-operative preparation of autologous bone marrow-derived CD34-enriched cellular products for cardiac therapy

Background and Aims. With the advent of regenerative therapy, there is renewed interest in the use of bone marrow as a source of adult stem and progenitor cells, including cell subsets prepared by immunomagnetic selection. Cell selection must be rapid, efficient and performed according to current good manufacturing practices. In this report we present a methodology for intra-operative preparation of CD34+ selected autologous bone marrow for autologous use in patients receiving coronary artery bypass grafts or left ventricular assist devices. Methods and Results. We developed a rapid erythrocyte depletion method using hydroxyethyl starch and low-speed centrifugation to prepare large-scale (mean 359 mL) bone marrow aspirates for separation on a Baxter Isolex 300i immunomagnetic cell separation device. CD34 recovery after erythrocyte depletion was 68.3 ±20.2%, with an average depletion of 91.2 ±2.8% and an average CD34 content of 0.58 ±0.27%. After separation, CD34 purity was 64.1 ±17.2%, with 44.3 ±Â± 26.1% recovery and an average dose of 5.0 ± 2.7 ×106 CD34+ cells/product. In uncomplicated cases CD34-enriched cellular products could be accessioned, prepared, tested for release and administered within 6 h. Further analysis of CD34+ bone marrow cells revealed a significant proportion of CD45-â^' CD34+ cells. Conclusions. Intra-operative immunomagnetic separation of CD34-enriched bone marrow is feasible using rapid low-speed Hetastarch sedimentation for erythrocyte depletion. The resulting CD34-enriched product contains CD45- cells that may represent non-hematopoietic or very early hematopoietic stem cells that participate in tissue regeneration. © 2011 Informa Healthcare.National Heart, Lung, and Blood Institute R01-HL-085819, N01-HB-37165This project was supported by Production Assistance for Cellular Therapy (PACT) under contract numbers N01-HB-37165 and R01-HL-085819 from the National Heart, Lung, and Blood Institute . The authors would like to acknowledge the technical assistance provided by Heather Stanczak and Eileen Koch for cell separation and enumeration, Deborah Livingston, Baxter Oncology, for assisting with the use of the Isolex device, Dr Amit Patel for collecting the bone marrow and injecting the product, G. Phillip Zorich for assisting with bone marrow harvests, and Dr James P. Bradley for providing bone marrow aspirates from orthopedic patients. Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper

Single center experience: long-term treatment results in thrombotic thrombocytopenic purpura

9th International Eurasian Hematology Oncology Congress (EHOC) -- OCT 17-20, 2018 -- Istanbul, TURKEYWOS: 000447176600043

Granulocyte transfusion in paediatric oncology patients with febrile neutropenia

38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT) -- APR 01-04, 2012 -- Geneva, SWITZERLANDWOS: 000302749201459…European Grp Blood & Marrow Transplantat (EBMT

Molecular characterization of ?-thalassemia in Adana, Turkey: A single center study

PubMedID: 20332613Background/Aim: ?-Thalassemia (?-thal) is a widespread genetic disorder throughout the world caused primarily by reduced synthesis of the ?-globin chains, and it has been found at a high incidence in Turkey. Our aim in this study was to determine the frequency and molecular properties of ?-thal in Adana, Turkey. Material and Methods: A total of 3,000 individuals comprising premarital couples or patients with anemia were screened between 2007 and 2008. Hematological parameters were analyzed using an automatic cell counter, and to detect the carriers of hemoglobin variants, high-performance liquid chromatography was used. Molecular screening of the ?-globin gene was carried out by an Alpha-Globin StripAssay® which is based on multiplex PCR for specific amplification. Results: We have identified 225 cases with ?-thal and found that the prevalence of ?-thal is 7.5% in this area. In molecular analyses, the ?-thal gene mutations ?3.7, ?4.2, - MED, - 20.5, ?PA-2?, ??? anti-3.7, and ?PA-1? were detected. Conclusion: Our results showed that the ?-thal mutations represent a great heterogeneity and that the -?3.7 deletion has the highest frequency in Adana. © 2010 S. Karger AG, Basel

Molecular Characterization of alpha-Thalassemia in Adana, Turkey: A Single Center Study

WOS: 000278131800001PubMed ID: 20332613Background/Aim: alpha-Thalassemia (alpha-thal) is a widespread genetic disorder throughout the world caused primarily by reduced synthesis of the alpha-globin chains, and it has been found at a high incidence in Turkey. Our aim in this study was to determine the frequency and molecular properties of alpha-thal in Adana, Turkey. Material and Methods: A total of 3,000 individuals comprising premarital couples or patients with anemia were screened between 2007 and 2008. Hematological parameters were analyzed using an automatic cell counter, and to detect the carriers of hemoglobin variants, high-performance liquid chromatography was used. Molecular screening of the alpha-globin gene was carried out by an Alpha-Globin StripAssay (R) which is based on multiplex PCR for specific amplification. Results: We have identified 225 cases with alpha-thal and found that the prevalence of alpha-thal is 7.5% in this area. In molecular analyses, the alpha-thal gene mutations alpha(3.7), alpha(4.2), (--MED), (--20.5), alpha(PA-2 alpha), alpha alpha alpha(anti-3.7), and alpha(PA-1)alpha were detected. Conclusion: Our results showed that the alpha-thal mutations represent a great heterogeneity and that the -alpha(3.7) deletion has the highest frequency in Adana. Copyright (C) 2010 S. Karger AG, Base